Jasper Therapeutics (JSPR) Cash from Operations (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Cash from Operations of 21906000.0 for Q4 2025, down 3.66% year-over-year from 22738854.11 in Q4 2024, and down 28.9% quarter-over-quarter from 16994000.0 in Q3 2025.
Jasper Therapeutics (JSPR) Cash from Operations (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Cash from Operations history runs 6 years deep, the most recent figure standing at 21906000.0 for Q4 2025.
- In Q4 2025, Cash from Operations fell 3.66% year-over-year to 21906000.0; the TTM figure through Dec 2025 stood at 77200000.0 (down 23.32% YoY), while the FY2025 annual figure was 77200000.0, down 23.32% from the prior year.
- Cash from Operations for Q4 2025 stood at 21906000.0, down from 16994000.0 in the prior quarter.
- The five-year high for Cash from Operations was 5791000.0 in Q2 2021, with the low at 22842000.0 in Q1 2025.
- The 5-year median for Cash from Operations is 13684000.0 (2023), against an average of 13573900.0.
- Peak annual rise in Cash from Operations reached 42.99% in 2021, while the deepest fall reached 3231.03% in 2021.
- Jasper Therapeutics' Cash from Operations stood at 14584000.0 in 2021, then grew by 12.92% to 12700000.0 in 2022, then sank by 30.02% to 16512000.0 in 2023, then retreated by 27.98% to 21132000.0 in 2024, then slipped by 3.66% to 21906000.0 in 2025.
- Business Quant data shows JSPR's Cash from Operations at 21906000.0 in Q4 2025, 16994000.0 in Q3 2025, and 15458000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 728.46 Mn |
| 10 | Jasper Therapeutics | 19.95 Mn | 19.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -21.91 Mn |
| Dec 31, 2025 | -21.91 Mn |
| Sep 30, 2025 | -16.99 Mn |
| Sep 30, 2025 | -16.99 Mn |
| Jun 30, 2025 | -15.46 Mn |
| Jun 30, 2025 | -15.46 Mn |
| Mar 31, 2025 | -22.84 Mn |
| Mar 31, 2025 | -22.84 Mn |
| Dec 31, 2024 | -21.13 Mn |
| Dec 31, 2024 | -21.13 Mn |
| Sep 30, 2024 | -14.07 Mn |
| Sep 30, 2024 | -14.07 Mn |
| Jun 30, 2024 | -11.70 Mn |
| Jun 30, 2024 | -11.70 Mn |
| Mar 31, 2024 | -15.70 Mn |
| Mar 31, 2024 | -15.70 Mn |
| Dec 31, 2023 | -16.51 Mn |
| Dec 31, 2023 | -16.51 Mn |
| Sep 30, 2023 | -11.99 Mn |
| Sep 30, 2023 | -11.99 Mn |